EGFR and lung adenocarcinoma: Research by Mezquita revealed that 90% of LFS patients with lung adenocarcinoma had driver gene mutations, mostly EGFR mutations, and the frequency of EGFR mutations was higher than that of the general lung adenocarcinoma population (Mezquita et al. 2020).